glp-1 obesity drug news today sep 30 2025 Agonists Market Report 2025-2033, By Product, Molecule, and Geo The next phase of the
Description
The approval pertains to the GLP-1 drug dubbed Xianweiying also known as ecnoglutide which Pfizer has just acquired in a billion-dollar deal.
Given its multi-target efficacy and botanical safety profile, BBR represents a cost-effective adjuvant for obesity management, particularly in resource-limited settings
Primary outcomes included changes in TTR, INR, and INR recheck frequency
Get a personalized plan, provider review, and ongoing supportall with a simple online process.
Here's what experts think.
